On March 31, 2021, the U.S. Food and Drug Administration (FDA) approved isatuximab in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma who have received one to three prior lines of therapy.
Read the FDA announcement.
Read the Sanofi announcement.
Posted 4/1/2021
Recognizing the critical role advanced practice providers and allied health professionals play in the care continuum, the American Oncology Network provides infrastructure, leadership, and professional growth opportunities to empower these members of the cancer care team to practice at the top of their license.
